Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Other Non-Current Assets (2019 - 2025)

Historic Other Non-Current Assets for Keros Therapeutics (KROS) over the last 7 years, with Q3 2025 value amounting to $1.4 million.

  • Keros Therapeutics' Other Non-Current Assets changed 0.0% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $2.1 million for FY2024, which is 19.49% up from last year.
  • Per Keros Therapeutics' latest filing, its Other Non-Current Assets stood at $1.4 million for Q3 2025, which was down 0.0% from $1.4 million recorded in Q2 2025.
  • Keros Therapeutics' 5-year Other Non-Current Assets high stood at $2.1 million for Q4 2024, and its period low was $115000.0 during Q1 2021.
  • Its 5-year average for Other Non-Current Assets is $1.3 million, with a median of $1.3 million in 2021.
  • Per our database at Business Quant, Keros Therapeutics' Other Non-Current Assets soared by 105478.26% in 2021 and then tumbled by 866.62% in 2023.
  • Quarter analysis of 5 years shows Keros Therapeutics' Other Non-Current Assets stood at $1.3 million in 2021, then changed by 0.0% to $1.3 million in 2022, then skyrocketed by 54.63% to $2.1 million in 2023, then increased by 0.19% to $2.1 million in 2024, then fell by 29.52% to $1.4 million in 2025.
  • Its Other Non-Current Assets stands at $1.4 million for Q3 2025, versus $1.4 million for Q2 2025 and $1.4 million for Q1 2025.